Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans.

Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S.

Drug Metab Dispos. 2007 Feb;35(2):240-5. Epub 2006 Nov 1.

2.

Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans.

Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S.

Drug Metab Dispos. 2006 Jan;34(1):69-74. Epub 2005 Oct 12.

3.

Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo.

Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y.

Clin Pharmacol Ther. 2008 Jan;83(1):61-9. Epub 2007 May 9.

PMID:
17495878
4.
5.

In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes.

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A.

Clin Pharmacol Ther. 2005 May;77(5):415-26.

6.

Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea.

Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK.

Mol Nutr Food Res. 2008 Jul;52(7):755-63. doi: 10.1002/mnfr.200600300.

7.

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK.

J Clin Invest. 1999 Jul;104(2):147-53. Erratum in: J Clin Invest 2002 Aug;110(4):571.

8.

Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S.

J Clin Pharmacol. 2006 Feb;46(2):201-13.

9.

Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.

Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A.

Clin Pharmacol Ther. 2011 Feb;89(2):234-42. doi: 10.1038/clpt.2010.271. Epub 2010 Dec 29.

PMID:
21191377
10.

Impact of ginkgo biloba on the pharmacokinetics of digoxin.

Mauro VF, Mauro LS, Kleshinski JF, Khuder SA, Wang Y, Erhardt PW.

Am J Ther. 2003 Jul-Aug;10(4):247-51.

PMID:
12845387
11.

Influence of goldenseal root on the pharmacokinetics of indinavir.

Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ.

J Clin Pharmacol. 2003 Nov;43(11):1283-8.

PMID:
14551183
12.

Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.

Brophy DF, Israel DS, Pastor A, Gillotin C, Chittick GE, Symonds WT, Lou Y, Sadler BM, Polk RE.

Antimicrob Agents Chemother. 2000 Apr;44(4):978-84.

13.

Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?

Baris N, Kalkan S, G√ľneri S, Bozdemir V, Guven H.

Eur J Clin Pharmacol. 2006 Jul;62(7):535-8. Epub 2006 Jun 10.

PMID:
16767433
14.

Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.

Zussman BD, Kelly J, Murdoch RD, Clark DJ, Mbchb, Schubert C, Collie H.

Clin Ther. 2001 Jun;23(6):921-31.

PMID:
11440291
15.

Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.

Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K.

Clin Pharmacol Ther. 2002 Aug;72(2):209-19.

PMID:
12189368
16.

The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers.

Tsutsumi K, Kotegawa T, Kuranari M, Otani Y, Morimoto T, Matsuki S, Nakano S.

J Clin Pharmacol. 2002 Oct;42(10):1159-64.

PMID:
12362931
17.
18.

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

Niemi M, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2001 Jul;70(1):58-65.

PMID:
11452245
19.

Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.

J Pharm Sci. 2013 Sep;102(9):3161-73. doi: 10.1002/jps.23607. Epub 2013 May 19.

PMID:
23686764
20.

Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY.

Clin Pharmacol Ther. 2002 Sep;72(3):276-87.

PMID:
12235448

Supplemental Content

Support Center